April 2012 Drug Information Update - Pharmacy Benefits ...

More documents

Recommendations

Info

a substantial improvement in their symptoms than those taking a drug-free placebo pill, regardless of how severe those symptoms were to begin with. Article link: http://www.reuters.com/article/2012/03/07/us-studyantidepressantsidUSTRE82623V20120307 Source website: http://www.reuters.com/ Alexion drug offers hope for rare, deadly disorder March 7, 2012 An experimental therapy for a rare, often fatal genetic disorder appears to offer hope for infants and very young children with the condition, according to data from a small clinical trial reported in the New England Journal of Medicine on Wednesday. The enzyme-replacement drug, asfotase alfa, acquired by Alexion Pharmaceuticals Inc with its $610 million purchase of Canada-based Enobia Pharma, could become the first approved treatment for the metabolic disease hypophosphatasia, or HPP. Article link: http://www.chicagotribune.com/health/sns-rt-us-alexionhypophosphatasiatre82621f-20120307,0,7147932.story Source website: http://www.chicagotribune.com/ Trial Shows Benefit in Using Prostate Cancer Drug Early March 8, 2012 Johnson & Johnson said Thursday that its new drug for prostate cancer was effective when used earlier during treatment than it is now, potentially broadening its use and also posing a competitive threat to a rival drug, Dendreon’s Provenge. Johnson & Johnson’s drug, called Zytiga, was approved in April for use in men with advanced prostate cancer who had already tried chemotherapy using the drug docetaxel. Article link: http://www.nytimes.com/2012/03/09/business/trial-shows-benefit-in-earlier-useofzytiga-for-prostate-cancer.html?_r=2 Source website: http://www.nytimes.com/ Pfizer Calls Early End To Celebrex Safety Study In Children March 9, 2012 Pfizer Inc. has terminated a long-term safety study of its blockbuster painkiller Celebrex in juvenile arthritis patients, citing difficulties in recruiting patients and a low rate of adverse events. New York-based Pfizer had agreed to conduct the study to address safety concerns in connection with the U.S. Food and Drug Administration's 2006 approval of the use of Celebrex to treat juvenile idiopathic arthritis. The FDA said at the time the use of Celebrex by adults suggested the possibility of longer-term cardiovascular problems. Article link: http://www.nasdaq.com/article/pfizer-calls-early-end-to-celebrex-safety-studyinchildren-20120309-00729 Source website: http://www.nasdaq.com/ Leukemia No Longer a Death Sentence as 90% of Children Live March 12, 2012 Childhood leukemia, once considered a death sentence, is now curable in nine out of 10 children, according to a study. Five-year survival rates for children diagnosed with acute lymphoblastic leukemia, the most common type in the young, rose to 90 percent in the years 2000 to 2005 from 84 percent in 1990 to 1994, according to research today in the Journal of Clinical Oncology. 16
Survival increased for all groups of children, except for infants 1-years-old and younger, the study said. Article link: http://www.bloomberg.com/news/2012-03-12/leukemia-no-longer-a-deathsentenceas-90-of-children-live-study-shows.html Source website: http://www.bloomberg.com/ Can Statins Prevent Parkinson's Disease? March 12, 2012 It's too early to say, but study suggests younger users may gain some benefit. People taking popular cholesterol-lowering drugs called statins may have a slightly lower risk than others of developing Parkinson's disease, new research suggests. This effect may be even more pronounced among people younger than 60, according to the study published in the March issue of Archives of Neurology. Article link: http://consumer.healthday.com/Article.asp?AID=662667 Source website: http://consumer.healthday.com/ One Antibiotic Appears to Ease Severe E. Coli Infection March 13, 2012 Small study looked at bacteria that caused German outbreak. Patients suffering from a strain of E. coli that produces Shiga toxin, which can be deadly, appear to respond to the antibiotic azithromycin (Zithromax), according to German researchers. Article link: http://consumer.healthday.com/Article.asp?AID=662723 Source website: http://consumer.healthday.com/ Experimental Pill May Ease Multiple Sclerosis Disability March 14, 2012 Latest trial shows laquinimod can also help prevent relapse. Yet another orally taken medication shows some promise in preventing relapse and disability for people with relapsing-remitting multiple sclerosis, a new report suggests. In the new study, laquinimod reduced the annual relapse rate by 23 percent, and disability progression by 36 percent. Article link: http://consumer.healthday.com/Article.asp?AID=662753 Source website: http://consumer.healthday.com/ Ibuprofen may ward off altitude sickness March 20, 2012 Ibuprofen has been used for decades to treat pain. Now, research suggests the drug's antiinflammatory properties also may help prevent the piercing headaches and other symptoms of altitude sickness. A small new study, published this week in the Annals of Emergency Medicine, found that people who took four 600-milligram doses of ibuprofen over a 24-hour period in which they ascended to 12,570 feet above sea level were less likely to experience altitude sickness than people taking a placebo. Article link: http://thechart.blogs.cnn.com/2012/03/20/ibuprofen-may-ward-off-altitude-sickness/ Source website: http://www.cnn.com/ Hippocrates’s 3-Cent Aspirin a Day May Keep Cancer at Bay Mar 21, 2012 Aspirin, the 3-cent painkiller whose origins can be traced to Hippocrates, reduces the chances of 17
Page 1 and 2: April 2012 Drug Information Update
Page 3 and 4: First-Time Generics GENERIC DRUG NA
Page 5 and 6: GENERAL ANESTHETICS, INJECTABLE MID
Page 7 and 8: Gruenhaupt, Mark R.Ph. Argus Health
Page 9 and 10: Statin Drugs - Drug Safety Communic
Page 11 and 12: Vytorin (ezetimibe/simvastatin) Tab
Page 13 and 14: low blood sugar (hypoglycemia) in p
Page 15: Some women with depression who beco
Page 19 and 20: finding that it also may reduce the
Page 21 and 22: Syringes (2 mL size), Rx only. NDC
Page 23 and 24: Patheon Pharmaceuticals Inc., Cinci
Page 25 and 26: 50-ct. bottles (NDC 0067-6238-50);
Page 27 and 28: PRODUCT (Class II) 1) Ventolin HFA
Page 29 and 30: Lot #: 0693, Exp: 10/2012 RECALLING
Page 31 and 32: 24 (Display case UPC# 3030045074923
Page 33 and 34: CODE Lot # 139961 RECALLING FIRM/MA
Page 35 and 36: Reason for the Shortage • Teva co
Page 37 and 38: Reason for the Shortage • Ben Ven
Page 39 and 40: Products Affected - Description Gan
Page 41 and 42: 37.5 mg/25 mg, 1000 count (NDC 0078
Page 43 and 44: Acyclovir tablets, Major 400 tablet
Page 45 and 46: 500 mg, 100 count (NDC 63304-0726-0
Page 47 and 48: 750 mg tablets, 100 count (NDC 1013
Page 49 and 50: • Bedford Laboratories has multip
Page 51 and 52: Daunorubicin Hydrochloride Injectio
Page 53 and 54: Ciprofloxacin Immediate-Release Tab
Page 55 and 56: • APP had tobramycin 40 mg/mL pre
Page 57 and 58: • Ben Venue voluntarily suspended
Page 59 and 60: 50 mg/mL, 10 mL vial, package of 10
Page 61 and 62: 2 mL vial, preservative-free (NDC 6
Page 63 and 64: 5 mg single dose vial, package of 1
Page 65 and 66: 20 mL glass ampule, sterile pack (N
Page 67 and 68:
2 mL iSecure syringe (NDC 00406-112
Page 69 and 70:
Lidocaine 0.5% Xylocaine 0.5% injec
Page 71 and 72:
• Teva discontinued all ciproflox
Page 73 and 74:
Nicardipine hydrochloride injection
Page 75 and 76:
Article link: http://www.ashp.org/D
Page 77 and 78:
• Apotex had metformin products u
Page 79:
• Covis purchased all rights to F
show all

April 2012 Drug Information Update - Pharmacy Benefits ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?